CyBio AG
CyBio AG english
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
CyBio AG: Sales and EBIT Declined in First Six Months
Projected Figures Announced for Current Fiscal Year
Jena, August 28, 2001: CyBio AG, of Jena, Germany (Neuer Markt Securities
Identification No. 541230), achieved U.S. GAAP sales in the first half of 2001
of EUR 6.83 million, which is about 30% below the same period in the previous
year (2000: EUR 10.18 million). Earnings before interest and taxes (EBIT) were
EUR -7.88 million and were also lower than in the prior-year period (2000: EUR –
1.40 million). The decline in sales revenues and earnings was primarily a result
of lower unit sales. EBIT was defined by expenses in the amount of EUR 2.10
million that were related to the stock option program without affects on
liquidity (2000: EUR 2.21 million).
CyBio’s business in Asia was favorable, however, and contrary to the
general trend. In comparison to 2000 (EUR 0.65 million), sales here were doubled
to more than EUR 1.22 million in the first half of 2001. CyBio AG expects
additional impetus for the Asian market from the conclusion of a new dealer
contract with the Korean CM Corporation.
The realignment of the sales structure initiated at the beginning of the
year and the general economic condition – in particular the consolidation of the
pharmaceuticals industry – are the most important factors behind the recent
development of business at CyBio AG. In order to boost unit sales again in the
near future, the company has introduced the new sales structure and thus
anticipated the necessary adaptation to the market.
In light of the development in the first six months, the executive board
of the biotech company expects total sales for fiscal 2001 to be lower than in
the previous year.
CyBio has placed an order considereing an investment. Therefore, CyBio
starts to buy back shares in order to use them as acquisition currency. (cf.
Adhoc 20.08.2001)
Contact: Cornelia Todt IR / PR; Göschwitzer Str. 40; 07745 Jena
Tel. 03641 / 35 14 25; Fax. 03641 / 35 13 60; E-mail: cornelia.todt@cybio-ag.com
end of ad-hoc-announcement (c)DGAP 28.08.2001
——————————————————————————–
WKN: 541230; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
280807 Aug 01
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden